TAPRIZOSIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H26N6O4S
Molecular Weight	506.5788
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COc1cc2c(c(-c3ccccn3)c1OC)c(=N)[nH]c(n2)N4CCc5c(cccc5NS(=O)(=O)C)C4

InChI

InChIKey=OLYXPBZBZBVRGD-UHFFFAOYSA-N

InChI=1S/C25H26N6O4S/c1-34-20-13-19-22(21(23(20)35-2)18-8-4-5-11-27-18)24(26)29-25(28-19)31-12-10-16-15(14-31)7-6-9-17(16)30-36(3,32)33/h4-9,11,13,30H,10,12,14H2,1-3H3,(H2,26,28,29)

HIDE SMILES / InChI

Molecular Formula	C25H26N6O4S
Molecular Weight	506.5788
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17932223

Taprizosin (also known as UK-338,003) is an alpha1A-adrenoceptor antagonist that was developed for the treatment of benign prostatic hyperplasia. However, this compound possesses poor oral absorption.

Approval Year

PubMed

Title	Date	PubMed
Investigation of regional mechanisms responsible for poor oral absorption in humans of a modified release preparation of the alpha-adrenoreceptor antagonist, 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (UK-338,003): the rational use of ex vivo intestine to predict in vivo absorption.	2008 Jan	17932223

Substance Class	Chemical Created by `admin` on `Sat Jun 26 06:34:40 UTC 2021` Edited by `admin` on `Sat Jun 26 06:34:40 UTC 2021`
Record UNII	EQ8YV2D86Y
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TAPRIZOSIN

Official Name

English

TAPRIZOSIN [INN]

Common Name

English

UK-338,003

Code

English

UK-338003

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C29713